Last reviewed · How we verify
GD2, PSMA and CD276 CAR-T cells
GD2, PSMA and CD276 CAR-T cells is a Biologic drug developed by Shenzhen Geno-Immune Medical Institute. It is currently in Phase 1 development.
Shenzhen Geno-Immune Medical Institute is developing a novel CAR-T therapy targeting GD2, PSMA, and CD276 for the treatment of neuroblastoma and sarcomas. Currently in Phase 1 and Phase 2 trials, this therapy represents a promising approach in immuno-oncology, leveraging the specificity of CAR-T cells to target multiple tumor antigens simultaneously.
At a glance
| Generic name | GD2, PSMA and CD276 CAR-T cells |
|---|---|
| Sponsor | Shenzhen Geno-Immune Medical Institute |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GD2, PSMA and CD276 CAR-T cells CI brief — competitive landscape report
- GD2, PSMA and CD276 CAR-T cells updates RSS · CI watch RSS
- Shenzhen Geno-Immune Medical Institute portfolio CI
Frequently asked questions about GD2, PSMA and CD276 CAR-T cells
What is GD2, PSMA and CD276 CAR-T cells?
GD2, PSMA and CD276 CAR-T cells is a Biologic drug developed by Shenzhen Geno-Immune Medical Institute.
Who makes GD2, PSMA and CD276 CAR-T cells?
GD2, PSMA and CD276 CAR-T cells is developed by Shenzhen Geno-Immune Medical Institute (see full Shenzhen Geno-Immune Medical Institute pipeline at /company/shenzhen-geno-immune-medical-institute).
What development phase is GD2, PSMA and CD276 CAR-T cells in?
GD2, PSMA and CD276 CAR-T cells is in Phase 1.